Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Gliosarcoma 2Glioblastoma 2Central Nervous System Neoplasms 2Prostatic Neoplasms 1Oligodendroglioma 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Lung Neoplasms 1Glioma 1Brain Neoplasms 1Astrocytoma 1Adrenocortical Carcinoma 1

Interventions

Cyclophosphamide 59Dexamethasone 56Melphalan 48Peripheral Blood Stem Cell Transplantation 37Busulfan 34Bortezomib 32fludarabine phosphate 29Lenalidomide 27Filgrastim 27Tacrolimus 24Antilymphocyte Serum 24Thalidomide 22Mycophenolic Acid 22Radiotherapy 21Methotrexate 15Cyclosporine 15Etoposide 14sargramostim 13Granulocyte Colony-Stimulating Factor 11Whole-Body Irradiation 10Methylprednisolone 10Interferon-alpha 10fludarabine 9daratumumab 9Carmustine 9carfilzomib 7Rituximab 7Prednisone 7Cytarabine 7Cord Blood Stem Cell Transplantation 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms, Plasma Cell × Suramin × Clear all
NCT00002652 2013-02-04

Suramin in Treating Patients With Refractory or Relapsed Multiple Myeloma or Castleman's Disease

National Cancer Institute (NCI)

Phase 2 Completed
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡